Skip to main content

MoneyWorks4Me

Sanofi India - Quaterly Results

30 Oct 2026 Evaluate
The quarter ended September 2026 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 4917.00 millions.The Profit  for the quarter ended September 2026 of  Rs. 1167.00  millions  grew by 53.55% from Rs. 760.00 millions.Operating profit for the quarter ended September 2026 rose to 1667.00 millions as compared to 1391.00 millions of corresponding quarter ended September 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202512 202412 % Var
Sales 4917.00 4754.00 3.43 14017.00 14176.00 -1.12 18374.00 20132.00 -8.73
Other Income 55.00 49.00 12.24 161.00 169.00 -4.73 197.00 165.00 19.39
PBIDT 1667.00 1391.00 19.84 4354.00 4179.00 4.19 5110.00 5073.00 0.73
Interest 2.00 4.00 -50.00 8.00 11.00 -27.27 17.00 15.00 13.33
PBDT 1665.00 1114.00 49.46 4346.00 3895.00 11.58 4820.00 4681.00 2.97
Depreciation 88.00 91.00 -3.30 267.00 278.00 -3.96 373.00 367.00 1.63
PBT 1577.00 1023.00 54.15 4079.00 3617.00 12.77 4447.00 4314.00 3.08
TAX 410.00 263.00 55.89 1051.00 967.00 8.69 1180.00 1177.00 0.25
Deferred Tax 3.00 -49.00 -106.12 4.00 -52.00 -107.69 -49.00 -81.00 -39.51
PAT 1167.00 760.00 53.55 3028.00 2650.00 14.26 3267.00 3137.00 4.14
Equity 230.00 230.00 0.00 230.00 230.00 0.00 230.00 230.00 0.00
PBIDTM(%) 33.90 29.26 15.87 31.06 29.48 5.37 27.81 25.20 10.37
Peers
Company Name CMP
Sun Pharma. Inds. 1778.25
Dr. Reddys Labs. 1350.20
Cipla 1380.00
Lupin 2009.00
Zydus Lifesciences 1244.00
View more..